Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 6/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674557 | 1.00 | MAPT (0.55) | MAPTMAPK1TDP1L3MBTL1KDM1A | |
| SCHEMBL21953183 | 0.87 | TDP1 (0.64) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL2800511 | 0.85 | ABCB1 (0.48) | MAPTKDM1ANPC1MAPK14MAOB | |
| SCHEMBL4267531 | 0.83 | MRGPRX4 (0.63) | MAPTMAPK1TDP1L3MBTL1KDM1A | |
| SCHEMBL22989897 | 0.82 | MAOB (0.51) | TDP1HTR1ANPC1MAOB | |
| SCHEMBL18171750 | 0.81 | TDP1 (0.58) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL30080427 | 0.81 | MAPT (0.58) | MAPTMAPK1TDP1L3MBTL1KDM1A | |
| SCHEMBL9706382 | 0.81 | MAPT (0.58) | MAPTMAPK1TDP1L3MBTL1KDM1A | |
| SCHEMBL23391605 | 0.81 | ALDH1A1 (0.46) | MAPK1L3MBTL1NPC1MRGPRX4 | |
| SCHEMBL4541564 | 0.81 | KDM1A (0.56) | MAPTMAPK1TDP1L3MBTL1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320227-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2025-10-16 | — | — | US | disclosed |
| WO-2023232966-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023218423-A1 | INDAZOLES AND THEIR USE IN METHODS FOR TREATING 5-HT2 RESPONSIVE CONDITIONS | ELEUSIS THERAPEUTICS US, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-2638040-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | MAPT 1099/4885MAPK1 2974/4885TDP1 4277/4885 |
| US-20060264435-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | MAPT 1655/4885MAPK1 2896/4885TDP1 3990/4885 |
| US-20250320227-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | HCRTR1, HCRTR2, NPY1R | MAPT 1634/4885MAPK1 1248/4885TDP1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.